Rifampicin
- Generic Name
- Rifampicin
- Brand Names
- Isonarif, Rifadin, Rifamate, Rifater, Rofact
- Drug Type
- Small Molecule
- Chemical Formula
- C43H58N4O12
- CAS Number
- 13292-46-1
- Unique Ingredient Identifier
- VJT6J7R4TR
- Background
A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)
- Indication
Rifampin is indicated for the treatment of tuberculosis and tuberculosis-related mycobacterial infections. In combination with pyrazinamide and isoniazid, it is used in the initial phase of the short-course treatment of pulmonary tuberculosis.
- Associated Conditions
- Cholestatic pruritus, MRSA Infections, Prosthetic Joint Infections, Asymptomatic Neisseria meningitidis carrier of the nasopharynx, Initial phase Tuberculosis, Late phase Tuberculosis
- Associated Therapies
- Antibacterial therapy
A Safety and Efficacy Study of CC-90011 in Participants With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas
- Conditions
- Interventions
- First Posted Date
- 2016-08-23
- Last Posted Date
- 2024-04-19
- Lead Sponsor
- Celgene
- Target Recruit Count
- 75
- Registration Number
- NCT02875223
- Locations
- 🇮🇹
Local Institution - 201, Milano, Italy
🇯🇵Local Institution - 500, Kashiwa, Japan
🇯🇵Local Institution - 501, Chuo-ku, Tokyo, Japan
Pharmacokinetic, Safety, and Tolerability Study of Intranasally Administered Esketamine in Healthy Han Chinese, Korean, Japanese, and Caucasian Participants and the Effects of Rifampin on the Pharmacokinetics of Intranasally Administered Esketamine
- First Posted Date
- 2016-07-27
- Last Posted Date
- 2019-03-26
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 66
- Registration Number
- NCT02846519
Study to Evaluate the Effect of Cytochrome P450 (CYP) 3A Inhibition and Induction on the Pharmacokinetics of CC-220 in Healthy Subjects
- First Posted Date
- 2016-07-01
- Last Posted Date
- 2016-10-18
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 36
- Registration Number
- NCT02820935
- Locations
- 🇺🇸
PPD Development, LP, Austin, Texas, United States
Study to Assess Pharmacokinetic Drug-Drug Interaction Between Avatrombopag When Co-Administered With Fluconazole, Itraconazole, or Rifampin in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2016-06-22
- Last Posted Date
- 2017-03-09
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT02809768
Drug-Interaction Study to Evaluate the Effect of Rifampin, a Potent CYP3A4 Inducer, on the Systemic Exposure of Pacritinib in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2016-06-21
- Last Posted Date
- 2023-09-15
- Lead Sponsor
- CTI BioPharma
- Target Recruit Count
- 18
- Registration Number
- NCT02807116
- Locations
- 🇺🇸
Covance Clinical Research Unit, Daytona Beach, Florida, United States
A Study To Evaluate The Effect Of Rifampin On Pharmacokinetics Of PF-06463922 In Healthy Volunteers
- First Posted Date
- 2016-06-17
- Last Posted Date
- 2019-01-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT02804399
- Locations
- 🇺🇸
Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States
A Clinical Study to Investigate the Effect of Gemfibrozil or Rifampicin on Blood Concentrations of Selexipag in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2016-05-12
- Last Posted Date
- 2016-07-21
- Lead Sponsor
- Actelion
- Target Recruit Count
- 40
- Registration Number
- NCT02770222
- Locations
- 🇩🇪
Investigator Site, Kiel, Germany
A Study to Assess the Effects of Itraconazole and Rifampicin on the Single-Dose Pharmacokinetics of JNJ-53718678 in Healthy Adults
- First Posted Date
- 2016-04-06
- Last Posted Date
- 2016-08-18
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 33
- Registration Number
- NCT02729467
Oral Switch During Treatment of Left-sided Endocarditis Due to Multi-susceptible Staphylococcus
- First Posted Date
- 2016-03-08
- Last Posted Date
- 2021-05-19
- Lead Sponsor
- University Hospital, Tours
- Target Recruit Count
- 324
- Registration Number
- NCT02701608
- Locations
- 🇫🇷
Service des Maladies infectieuses et Tropicales, Hôpital Jean Minjoz, CHU de Besançon, Besançon, France
🇫🇷Service de Réanimation médicale, Hôpital St André, CHU de Bordeaux, Bordeaux, France
🇫🇷Service de Médecine interne, Hôpital Ambroise Paré, APHP, Boulogne Billancourt, France
A Drug Interaction Study in Healthy Participants to Assess the Effect of Rifampin on the Pharmacokinetics of JNJ-42847922
- First Posted Date
- 2016-01-25
- Last Posted Date
- 2016-05-05
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 14
- Registration Number
- NCT02661893
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.